What a week! And there's still one day left.
Human Genome Sciences and Orexigen got the party started on Monday with their Lupus and diet drug data, respectively.
Onyx Pharmaceuticals was a surprise guest with its mid-stage breast cancer results on Wednesday.
Bristol-Myers Squibb cranked up the volume late yesterday with its two-bagger for Medarex. And then this morning Celgene announced it had stopped a multiple myeloma study early because the drug appears to be working so well.
If there was ever any doubt, that's fast-building critical mass and proof positive of how drug data and deals move biopharma stocks.